All Stories

  1. Resistance of Enterobacterales causing community-acquired urinary tract infections in the Russian Federation in 2024: data from the RESOURCE-2 study

    Article • Urologiia, May 2026, Bionika Media

    Professor Vladimir V Rafalskiy

  2. Resolution of the expert forum “Interdisciplinary aspects of the management of patients with urinary tract infection and chronic pelvic pain. The role of nitrofurans in the treatment of urinary tract infection”

    Article • Urologiia, May 2026, Bionika Media

    Professor Vladimir V Rafalskiy

  3. Spontaneous reports of adverse reactions to methotrexate: retrospective analysis in the Russian Federation

    Article • FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology, May 2026, IRBIS

    Professor Vladimir V Rafalskiy

  4. Storage-induced spectral changes of human platelet-rich plasma revealed by SERS

    Article • Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy, February 2026, Elsevier

    Professor Vladimir V Rafalskiy

  5. Spectrum of pathogens and their antimicrobial resistance in cystitis, pyelonephritis, and prostatitis

    Article • Urologiia, December 2025, Bionika Media

    Professor Vladimir V Rafalskiy

  6. Pharmacoepidemiological analysis of drug therapy for asthenic syndrome as provided in Kaliningrad region

    Article • Research Results in Pharmacology, September 2025, Belgorod National Research University

    Professor Vladimir V Rafalskiy

  7. Assessment of the sensitivity of Eschericia coli to nitrofuran derivatives – an important issue in the context of growing antimicrobial resistance

    Article • Urologiia, July 2025, Bionika Media

    Professor Vladimir V Rafalskiy

  8. Analysis of pharmacotherapy practice in patients after myocardial infarction: results of a prospective open study «PROMETHEUS»

    Article • Siberian Journal of Clinical and Experimental Medicine, July 2025, Cardiology Research Institute

    Professor Vladimir V Rafalskiy

  9. Analysis of methotrexate use practice in patients with rheumatoid and psoriatic arthritis

    Article • FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology, May 2025, IRBIS

    Professor Vladimir V Rafalskiy

  10. Sers-based methodology for nanomolar methotrexate concentration detection for clinics

    Article • Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy, April 2025, Elsevier

    Professor Vladimir V Rafalskiy

  11. Tirzepatide for Obesity Treatment and Diabetes Prevention

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, March 2025, New England Journal of Medicine (NEJM/MMS)

    Professor Vladimir V Rafalskiy

  12. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies

    Article • The Lancet, January 2025, Elsevier

    Professor Vladimir V Rafalskiy

  13. Real-world data for monitoring antimicrobial resistance to urinary tract infection pathogens

    Article • Real-World Data & Evidence, December 2024, Publishing House OKI

    Professor Vladimir V Rafalskiy

  14. Spectral biomarkers of antiplatelet therapy effectiveness revealed by SERS

    Article • November 2024, SPIE

    Professor Vladimir V Rafalskiy

  15. Detection of methotrexate molecules in human plasma by SERS method

    Article • November 2024, SPIE

    Professor Vladimir V Rafalskiy

  16. Portable SERS device for antiplatelet therapy effectiveness investigation

    Article • November 2024, SPIE

    Professor Vladimir V Rafalskiy

  17. Cardiovascular events in patients with psoriasis and psoriatic arthritis treated with JAK/TYK inhibitors: A systematic review and meta‐analysis

    Article • Journal of the European Academy of Dermatology and Venereology, November 2024, Wiley

    Professor Vladimir V Rafalskiy

  18. Toxic Reactions in Probable and Confirmed Methotrexate Overdose in Rheumatology Patients: A Case Series

    Article • Safety and Risk of Pharmacotherapy, November 2024, SCEEMP

    Professor Vladimir V Rafalskiy

  19. Application of Raman spectroscopy using an original optical sensor to assess the laboratory efficacy of antiplatelet drugs

    Article • Medical alphabet, November 2024, Alfmed LLC

    Professor Vladimir V Rafalskiy

  20. Risankizumab for Ulcerative Colitis

    Article • JAMA, September 2024, American Medical Association (AMA)

    Professor Vladimir V Rafalskiy

  21. Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, July 2024, New England Journal of Medicine (NEJM/MMS)

    Professor Vladimir V Rafalskiy

  22. Dataset of human platelets SERS spectra from individuals with acute coronary syndrome

    Article • Data in Brief, June 2024, Elsevier

    Professor Vladimir V Rafalskiy

  23. Enhancing the Efficacy and Safety of Methotrexate Treatment: A Focus on Drug Interactions (Review)

    Article • Safety and Risk of Pharmacotherapy, April 2024, SCEEMP

    Professor Vladimir V Rafalskiy

  24. Search for predictors of complications of acute coronary syndrome with ST segment elevation – protocol of a prospective open cohort study PROMETHEUS

    Article • Siberian Journal of Clinical and Experimental Medicine, April 2024, Cardiology Research Institute

    Professor Vladimir V Rafalskiy

  25. Modern doctors' view on the problem of diagnostics and treatment of asthenic syndrome in different regions of the Russian Federation

    Article • Research Results in Pharmacology, January 2024, Belgorod National Research University

    Professor Vladimir V Rafalskiy

  26. Raman spectra simulation of antiplatelet drug-platelet interaction using DFT

    Article • Scientific Reports, January 2024, Springer Science + Business Media

    Professor Vladimir V Rafalskiy

  27. Analysis of the characteristics of pharmacotherapy for outpatients with cardiovascular diseases in the Russian Federation based on the results of an online survey of doctors

    Article • Lechaschi Vrach, December 2023, Open Systems Publications

    Professor Vladimir V Rafalskiy

  28. Application of SERS method for detection of methotrexate molecules in human plasma

    Article • November 2023, SPIE

    Professor Vladimir V Rafalskiy

  29. Surface-enhanced Raman spectroscopy for searching pharmacodynamic predictors of response to antiplatelet therapy

    Article • Siberian Journal of Clinical and Experimental Medicine, August 2023, Cardiology Research Institute

    Professor Vladimir V Rafalskiy

  30. Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials

    Article • International Journal of Obesity, July 2023, Springer Science + Business Media

    Professor Vladimir V Rafalskiy

  31. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, June 2023, New England Journal of Medicine (NEJM/MMS)

    Professor Vladimir V Rafalskiy

  32. Mathematical Analysis of Raman Spectra Data Arrays Using Machine Learning Algorithms

    Article • Journal of Biomedical Photonics & Engineering, June 2023, Samara State Aerospace University

    Professor Vladimir V Rafalskiy

  33. 1704-P: Efficacy and Safety of Tirzepatide for Weight Loss—A Meta-analysis of Randomized Controlled Trials

    Article • Diabetes, June 2023, American Diabetes Association

    Professor Vladimir V Rafalskiy

  34. Assessment of Safety and Prophylactic Efficacy of the EpiVacCorona Peptide Vaccine for COVID-19 Prevention (Phase III)

    Article • Vaccines, May 2023, MDPI AG

    Professor Vladimir V Rafalskiy

  35. Dynamics of endothelial function indexes in patients with post-Covid syndrome using a combination drug of ethylmethylhydroxyperidine succinate/vitamin B6

    Article • Research Results in Pharmacology, May 2023, Belgorod National Research University

    Professor Vladimir V Rafalskiy

  36. JAK-inhibitors: clinical pharmacology and application perspectives

    Article • Reviews on Clinical Pharmacology and Drug Therapy, March 2023, ECO-Vector LLC

    Professor Vladimir V Rafalskiy

  37. Specifics of motivation of volunteers participating in in a clinical trial of the COVID-19 vaccine

    Article • Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice, March 2023, Publishing House OKI

    Professor Vladimir V Rafalskiy

  38. Study of human platelets spectral homogeneity by SERS technique

    Article • January 2023, American Institute of Physics

    Professor Vladimir V Rafalskiy

  39. Application of vibrational spectroscopy and nuclear magnetic resonance methods for drugs pharmacokinetics research

    Article • Drug Metabolism and Personalized Therapy, September 2022, De Gruyter

    Professor Vladimir V Rafalskiy

  40. Analysis of eye-tracking data during the Sternberg working memory task in subjects with asthenic syndrome

    Article • September 2022, Institute of Electrical & Electronics Engineers (IEEE)

    Professor Vladimir V Rafalskiy

  41. Study on Tirzepatide's Effectiveness in Treating Obesity

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, July 2022, New England Journal of Medicine (NEJM/MMS)

    Professor Vladimir V Rafalskiy

  42. Spectral homogeneity of human platelets investigated by SERS

    Article • PLOS One, May 2022, PLOS

    Professor Vladimir V Rafalskiy

  43. The results of phase III multicenter open randomized controlled study REM-Chol-III-16 in patients with intrahepatic cholestasis syndrome caused by chronic diffuse liver diseases

    Article • Terapevticheskii arkhiv, December 2021, LLC Obyedinennaya Redaktsiya

    Professor Vladimir V Rafalskiy

  44. Application of the spectrofluorimetric research method to study the complexes «Pt NPs -platelets»

    Article • October 2021, SPIE

    Professor Vladimir V Rafalskiy

  45. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, September 2021, New England Journal of Medicine (NEJM/MMS)

    Dr Nazarii Kobyliak, Professor Vladimir V Rafalskiy

  46. Spectral and time-resolved photoluminescence of human platelets doped with platinum nanoparticles

    Article • PLOS One, September 2021, PLOS

    Professor Vladimir V Rafalskiy

  47. NMR spectroscopy reveals acetylsalicylic acid metabolites in the human urine for drug compliance monitoring

    Article • PLOS One, March 2021, PLOS

    Professor Vladimir V Rafalskiy

  48. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, January 2021, New England Journal of Medicine (NEJM/MMS)

    Professor John GF Cleland, Professor Vladimir V Rafalskiy, Professor john j mcmurray

  49. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, January 2021, New England Journal of Medicine (NEJM/MMS)

    Professor Deepak L Bhatt, Professor Vladimir V Rafalskiy

  50. The use of antiviral drug based on technologically processed antibodies to interferon-γ, CD4 receptor and histamine in the treatment of influenza in adults: results of a multicenter open-label randomized comparative trial with oseltamivir

    Article • Infekcionnye bolezni, January 2021, Dynasty Publishing House

    Professor Vladimir V Rafalskiy

  51. Resistance of pathogens of community-acquired urinary tract infections: lessons from Russian multicenter microbiological studies. Part II

    Article • Urologiia, November 2020, Bionika Media

    Professor Vladimir V Rafalskiy

  52. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC‐HF baseline characteristics and comparison with contemporary clinical trials

    Article • European Journal of Heart Failure, October 2020, Wiley

    Professor John GF Cleland, Professor Vladimir V Rafalskiy, Professor john j mcmurray

  53. Photophysical properties of nanoparticle-dye-protein complexes for fluorescent labeling purposes

    Article • October 2020, SPIE

    Professor Vladimir V Rafalskiy

  54. Surface-enhanced Raman spectroscopy for antiplatelet therapy effectiveness assessment

    Article • Laser Physics Letters, March 2020, Institute of Physics Publishing

    Professor Vladimir V Rafalskiy

  55. Prospects for Raman spectroscopy in cardiology

    Article • CARDIOVASCULAR THERAPY AND PREVENTION, March 2020, Silicea - Poligraf, LLC

    Professor Vladimir V Rafalskiy

  56. Dataset of human platelets in healthy and individuals with cardiovascular pathology obtained by Surface-enhanced Raman spectroscopy

    Article • Data in Brief, January 2020, Elsevier

    Professor Vladimir V Rafalskiy

  57. Treatment of acute respiratory viral infections: results of a multicenter, double-blind, placebo-controlled, randomized clinical trial

    Article • Infekcionnye bolezni, January 2020, Dynasty Publishing House

    Professor Vladimir V Rafalskiy

  58. Single human platelet study using surface-enhanced Raman spectroscopy as a perspective tool for antiplatelet therapy effectiveness prediction

    Article • November 2019, SPIE

    Professor Vladimir V Rafalskiy

  59. Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, October 2019, New England Journal of Medicine (NEJM/MMS)

    Professor Vladimir V Rafalskiy, Professor John GF Cleland, Professor john j mcmurray

  60. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, September 2019, New England Journal of Medicine (NEJM/MMS)

    Professor Vladimir V Rafalskiy

  61. Distribution and antibiotic resistance profile of key gram-negative bacteria that cause community-onset urinary tract infections in the Russian Federation: RESOURCE multicentre surveillance 2017 study

    Article • Journal of Global Antimicrobial Resistance, September 2019, Elsevier

    Professor Vladimir V Rafalskiy

  62. Income Inequality and Outcomes in Heart Failure

    Article • JACC Heart Failure, April 2019, Elsevier

    Dr Joao Pedro Ferreira, Professor Vladimir V Rafalskiy, Professor john j mcmurray

  63. Antibiotic resistance of pathogens causing uncomplicated urinary tract infections in Russian Federation

    Article • Urology Herald, October 2018, Rostov State Medical University

    Professor Vladimir V Rafalskiy

  64. Growth differentiation factor‐15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM‐HF trial

    Article • European Journal of Heart Failure, September 2018, Wiley

    Professor Vladimir V Rafalskiy, Professor john j mcmurray

  65. EPIDEMIOLOGY OF UNCOMPLICATED OUTPATIENT URINARY TRACT INFECTIONS IN THE RUSSIAN FEDERATION

    Article • Urology Herald, July 2018, Rostov State Medical University

    Professor Vladimir V Rafalskiy

  66. Cost-of-Illness Analysis of Type 2 Diabetes Mellitus in the Russian Federation: Results from Russian multicenter observational pharmacoepidemiologic study of diabetes care for patients with type 2 diabetes mellitus (FORSIGHT-Т2DM)

    Article • Diabetes Mellitus, February 2018, Endocrinology Research Centre

    Professor Vladimir V Rafalskiy

  67. Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM‐HF

    Article • European Journal of Heart Failure, November 2017, Wiley

    Professor Vladimir V Rafalskiy

  68. Type of Atrial Fibrillation and Outcomes in Patients With Heart Failure and Reduced Ejection Fraction

    Article • Journal of the American College of Cardiology, November 2017, Elsevier

    Professor Vladimir V Rafalskiy

  69. Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation

    Article • Circulation Heart Failure, October 2017, Wolters Kluwer Health

    Professor Vladimir V Rafalskiy

  70. Resistance of urinary tract pathogens and the choice of antimicrobial therapy: deceptive simplicity

    Article • Urologiia, July 2017, Bionika Media

    Professor Vladimir V Rafalskiy

  71. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, June 2017, New England Journal of Medicine (NEJM/MMS)

    Professor Vladimir V Rafalskiy, luigi gnudi

  72. The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF

    Article • American Heart Journal, June 2017, Elsevier

    Professor john j mcmurray, Professor Vladimir V Rafalskiy

  73. Assessing routine healthcare pattern for type 2 diabetes mellitus in Russia: the results of рharmacoepidemiological study (FORSIGHT-DM2)

    Article • Diabetes Mellitus, March 2017, Endocrinology Research Centre

    Professor Vladimir V Rafalskiy

  74. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial

    Article • Diabetes Obesity and Metabolism, January 2017, Wiley

    Professor Vladimir V Rafalskiy

  75. LOW DOSAGE ACETYLSALICYLIC ACID: A VARIETY OF FORMULATIONS

    Article • CARDIOVASCULAR THERAPY AND PREVENTION, January 2017, Silicea - Poligraf, LLC

    Professor Vladimir V Rafalskiy

  76. Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction

    Article • European Journal of Heart Failure, November 2016, Wiley

    Professor Vladimir V Rafalskiy, Professor john j mcmurray

  77. Efficacy and safety of Ergoferon versus oseltamivir in adult outpatients with seasonal influenza virus infection: a multicenter, open-label, randomized trial

    Article • International Journal of Infectious Diseases, September 2016, Elsevier

    Professor Vladimir V Rafalskiy

  78. Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background TherapyCLINICAL PERSPECTIVE

    Article • Circulation Heart Failure, September 2016, Wolters Kluwer Health

    Professor john j mcmurray, Professor Vladimir V Rafalskiy

  79. Sharing Data from Cardiovascular Clinical Trials — A Proposal

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, August 2016, New England Journal of Medicine (NEJM/MMS)

    Professor Vladimir V Rafalskiy, Professor Deepak L Bhatt

  80. Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization

    Article • Journal of the American College of Cardiology, July 2016, Elsevier

    Professor john j mcmurray, Professor Vladimir V Rafalskiy

  81. Importance of Clinical Worsening of Heart Failure Treated in the Outpatient SettingCLINICAL PERSPECTIVE

    Article • Circulation, April 2016, Wolters Kluwer Health

    Professor Vladimir V Rafalskiy, Professor john j mcmurray

  82. Study of pharmaceutical properties of low-dosage enteric-coated acetylsalicylic acid

    Article • CARDIOVASCULAR THERAPY AND PREVENTION, March 2016, Silicea - Poligraf, LLC

    Professor Vladimir V Rafalskiy

  83. Influenza Vaccination in Patients With Chronic Heart Failure

    Article • JACC Heart Failure, February 2016, Elsevier

    Professor john j mcmurray, Professor Vladimir V Rafalskiy

  84. Risk Related to Pre–Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection FractionCLINICAL PERSPECTIVE

    Article • Circulation Heart Failure, January 2016, Wolters Kluwer Health

    Professor Vladimir V Rafalskiy, Professor john j mcmurray

  85. Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes

    Article • Diabetes Obesity and Metabolism, December 2015, Wiley

    Professor Vladimir V Rafalskiy, luigi gnudi

  86. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, December 2015, New England Journal of Medicine (NEJM/MMS)

    Professor Vladimir V Rafalskiy, Professor john j mcmurray, Prof. Francisco Marin , Ponnusamy Saravanan

  87. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, December 2015, New England Journal of Medicine (NEJM/MMS)

    Professor Vladimir V Rafalskiy, Ponnusamy Saravanan

  88. Estimating the Long-Term Treatment Benefits of Sacubitril–Valsartan

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, December 2015, New England Journal of Medicine (NEJM/MMS)

    Professor john j mcmurray, Professor Vladimir V Rafalskiy

  89. Comparing LCZ696 With Enalapril According to Baseline Risk Using the MAGGIC and EMPHASIS-HF Risk Scores

    Article • Journal of the American College of Cardiology, November 2015, Elsevier

    Professor Vladimir V Rafalskiy, Professor john j mcmurray

  90. Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF

    Article • European Heart Journal, July 2015, European Society of Cardiology

    Professor john j mcmurray, Professor Vladimir V Rafalskiy

  91. Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo

    Article • American Heart Journal, May 2015, Elsevier

    Professor Vladimir V Rafalskiy, Professor john j mcmurray, Professor Tzung-Dau Wang, Professor Rayaz Ahmed Malik, Prof. Francisco Marin , Ponnusamy Saravanan

  92. Pharmacokinetic peculiarities of intravenous and oral ciprofloxacin administration in preoperative prophylaxis in patients with benign prostatic hyperplasia

    Article • Reviews on Clinical Pharmacology and Drug Therapy, December 2014, ECO-Vector LLC

    Professor Vladimir V Rafalskiy

  93. Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes

    Article • Diabetes Care, December 2014, American Diabetes Association

    Professor Vladimir V Rafalskiy

  94. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure

    Article • European Heart Journal, November 2014, European Society of Cardiology

    Professor john j mcmurray, Professor Vladimir V Rafalskiy

  95. Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure

    Article • Circulation, November 2014, Wolters Kluwer Health

    Professor Vladimir V Rafalskiy, Professor john j mcmurray, Professor Thomas Munzel or Muenzel, Dr William D Strain

  96. P9: Efficacy and safety of simeprevir in treatment naïve HCV genotype 1‐infected patients with METAVIR F2 fibrosis: QUEST‐1 and QUEST‐2 Phase III studies

    Article • Journal of Viral Hepatitis, October 2014, Wiley

    Professor Vladimir V Rafalskiy

  97. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, September 2014, New England Journal of Medicine (NEJM/MMS)

    Professor Vladimir V Rafalskiy, Professor john j mcmurray, Professor Thomas Munzel or Muenzel, Dr William D Strain

  98. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

    Article • The Lancet, August 2014, Elsevier

    Professor Vladimir V Rafalskiy

  99. Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)

    Article • European Journal of Heart Failure, June 2014, Wiley

    Professor john j mcmurray, Professor Vladimir V Rafalskiy

  100. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study

    Article • Hepatology, October 2013, Wiley

    Professor Vladimir V Rafalskiy

  101. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact

    Article • European Journal of Heart Failure, September 2013, Wiley

    Professor Vladimir V Rafalskiy, Professor john j mcmurray, Dr William D Strain

  102. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge in Russian practice

    Article • European Heart Journal, August 2013, European Society of Cardiology

    Professor Vladimir V Rafalskiy

  103. Sa2072 Simeprevir (TMC435) With Peginterferon/Ribavirin for Chronic HCV Genotype-1 Infection in Treatment-Nai;auve Patients: Results From QUEST-1, a Phase III Trial

    Article • Gastroenterology, May 2013, Elsevier

    Professor Vladimir V Rafalskiy

  104. 1425 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAÏVE PATIENTS: RESULTS FROM QUEST-1, A PHASE III TRIAL

    Article • Journal of Hepatology, April 2013, Elsevier

    Professor Vladimir V Rafalskiy

  105. Ferric Carboxymaltose Prevents Recurrence of Anemia in Patients With Inflammatory Bowel Disease

    Article • Clinical Gastroenterology and Hepatology, March 2013, Elsevier

    Professor Vladimir V Rafalskiy

  106. Eltrombopag before Procedures in Patients with Cirrhosis and Thrombocytopenia

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, August 2012, New England Journal of Medicine (NEJM/MMS)

    Professor Vladimir V Rafalskiy

  107. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response

    Article • Hepatology, August 2010, Wiley

    Professor Vladimir V Rafalskiy

  108. 247 PREDICTING TREATMENT OUTCOME AMONG SLOW RESPONDERS: A RETROSPECTIVE ANALYSIS OF THE SUCCESS STUDY

    Article • Journal of Hepatology, April 2010, Elsevier

    Professor Vladimir V Rafalskiy

  109. P300 Does in vitro antimicrobial resistance predict clinical outcomes in urinary tract infections: systematic review and metaanalysis

    Article • International Journal of Antimicrobial Agents, July 2009, Elsevier

    Professor Vladimir V Rafalskiy

  110. PREVALENCE AND RISK FACTORS OF UNCOMPLICATED UTI: MULTICENTRE STUDY SONAR

    Article • European Urology Supplements, March 2008, Elsevier

    Professor Vladimir V Rafalskiy

  111. 3-5 DAYS FLUOROQUINOLONES THERAPY IS MORE EFFECTIVE FOR ACUTE UNCOMPLICATED CYSTITIS THEN SINGLE DOSE FOSFOMYCIN: SYSTEMATIC REVIEW AND META-ANALYSIS

    Article • European Urology Supplements, March 2008, Elsevier

    Professor Vladimir V Rafalskiy

  112. Antimicrobial susceptibility of pathogens isolated from adult patients with uncomplicated community-acquired urinary tract infections in the Russian Federation: two multicentre studies, UTIAP-1 and UTIAP-2

    Article • International Journal of Antimicrobial Agents, August 2006, Elsevier

    Professor Vladimir V Rafalskiy

  113. Quinolones for uncomplicated acute cystitis in women

    Article • Cochrane Database of Systematic Reviews, July 2006, Wiley

    Professor Vladimir V Rafalskiy

  114. Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, March 2006, New England Journal of Medicine (NEJM/MMS)

    Professor Daniel D Shouval, Professor Vladimir V Rafalskiy

  115. A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, March 2006, New England Journal of Medicine (NEJM/MMS)

    Professor Vladimir V Rafalskiy

  116. Quinolones for uncomplicated acute cystitis in women

    Article • April 2002, Wiley

    Professor Vladimir V Rafalskiy